Russia eyeing procurement of Roche's SMA drug

17 August 2021
russia_big

The Russian government may expand the list of purchased high-priced drugs for its needs by beginning purchases of risdiplam – a drug for treatment of spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent

Several days ago the Commission on the Formation of Lists of Drugs of the Russian Ministry of Health recommended the national government to include a second drug for the treatment of SMA, Evrysdi (risdiplam) which is produced by Swiss pharma giant Roche (ROG: SIX), in the list of essential and vital drugs in the Russian market.

According to some local analysts, the inclusion of risdiplam in the list of essential drugs will help adult patients with SMA to a greater extent, as for the majority of them procurements of the drug, so far, have been carried from regional budgets, which funding has significantly declined in recent months.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology